About Us
Science
Pipeline
- HMBD-001
- HMBD-501
News
Partnering
Patients
Contact
Join Us

SITC 2022: Anti-VISTA antibody HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T cell response

by hbs-admin on 16 November, 2022 in HMBD-002, Posters, Posters - 2022, Publications & Posters

<< Back to Publications

SITC 2022: Anti-VISTA antibody HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T cell response

16 November, 2022

VIEW POSTER

<< Back to News

PubPosts-HMBD-002 RelatedNews-HMBD-002

Previous Reading

SITC 2022: Trial in Progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

Next Reading

Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy

Subscribe to our updates

*indicates required

*Email Address

*First Name

*Last Name

*Company

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website. For questions about this mailing list, please email communications@hummingbirdbio.com

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

SITC 2022: Anti-VISTA antibody HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T cell response

SITC 2022: Anti-VISTA antibody HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T cell response

Leave a Reply Cancel reply